“…These include younger age, lower BMI, previous hypoglycaemic events, presence of individual micro-and macrovascular complications, duration of diabetes, duration of insulin treatment, type of insulin and number of insulin injections. [32][33][34][35][36][37] Finally, and as shown in the current study, the type of OAD administered as background therapy and the characteristics of the patients administered these different combinations can also impact on the risk of hypoglycaemia.…”